Experience is a biochemical intervention: a reconceptualization of "biologically based mental disorders"
DOI:
https://doi.org/10.33898/rdp.v16i61.942Keywords:
psychotherapy, placebo, mental disorders, medication, healthcare policyAbstract
Empirical evidence challenges the discriminant validity of the “biologically based mental illness” (BBMI) construct. Data indicate that interventions such as psychotherapy, placebo, and medication yield similar changes in brain function when effective. Drug and brain imaging studies show that psychological and biochemical phenomena can be manipulated reciprocally. Data suggest that mental disorders are biologically expressed, not epiphenomenal to a biological process. Suggestions are given for further research and alternative conceptualizations that may lead to changes in healthcare policy.
Downloads
References
Ackerman, D. L. & Greenland, S. (2002). Multivariate meta–analysis of controlled drug studies for obsessive–compulsive disorder. Journal of Clinical Psychopharmacology, 22(3), 309–317.
Addington, D., Addington, J., Patten, S., Remington, G., Moamai, J., Labelle, A. & Beauclair, L. (2002). Double–blind, placebo–controlled comparison of the efficacy of sertraline as treatment for a major depressive episode in patients with remitted schizophrenia. Journal of Clinical Psychopharmacology, 22, 20–25.
Baxter, L. R., JR., Schwartz, J. M., Bergman, K. S., Szuba, M. P., Guze, B. H., Mazziotta, J. C., Alazraki, A., Selin, C. E., Ferng, H.–K., Munford, P. & Phelps, M. E. (1992). Caudate glucose metabolic rate changes with both drug and behavior therapy for obsessive–compulsive disorder. Archives of General Psychiatry, 49, 681–689.
Brody, A. L., Saxena, S., Stoessel, P., Gillies, L. A., Fairbanks, L. A., Alborzian, S., Phelps, M. E., Huang, S.–C., Wu, H.–M., Ho, M. L., Jo, M. K., Au, S. C., Maidment, K. & Baxter, L. R. (2001). Regional brain metabolic changes in patients with major depression treated with either paroxetine or interpersonal therapy: Preliminary findings. Archives of General Psychiatry, 58, 631–640.
Cook, I. A., Leuchter, A. F., Morgan, M., Witte, E., Stubbeman, W. F., Abrams, M., Rosenberg, S. & Uijtdehaage, S. H. J. (2002). Early changes in prefrontal activity characterize clinical responders to antidepressants. Neuropsychopharmacology, 27(1), 120–131.
Faries, D. E., Heiligenstein, J. H., Tollefson, G. D. & Potter, W. Z. (2001). The double–blind variable placebo lead–in period: Results from two antidepressant clinical trials. Journal of Clinical Psychopharmacology, 21(6), 561–568.
Fisher, R. L. & Fisher, S. (1996). Antidepressants for children: Is scientific support necessary? Journal of Nervous and Mental Disease, 184(2), 99–102.
Foucault, M. (1988). Madness and civilization. New York: Vintage.
Freud, S. (1957). On narcissism: An introduction. In J. Strachey (Ed. And Trans.), The standard edition of the complete psychological works of Sigmund Freud (Vol. 14, pp. 73–102). London: Hogarth Press. (Original work published 1914)
Goldapple, K., Segal, Z., Garson, C., Bieling, P., Lau, M. & Mayberg, H. (2002, May). Effects of cognitive behavioral therapy on brain glucose metabolism in patients with major depression. Poster session presented at the annual meeting of the Society of Biological Psychiatry, Philadelphia, PA.
Gorenstein, C., Gentil, V., Melo, M., Lotufo–Neto, F. & Lauriano, V. (1998). Mood improvement in “normal” volunteers. Journal of Psychopharmacology, 12(3), 246–251.
Greenberg, R. P., Bornstein, R. F., Zborowski, M. J., Fisher, S. & Greenberg, M. D. (1994). A meta–analysis of fluoxetine outcome in the treatment of depression. Journal of Nervous and Mental Disease, 182, 547–551.
Greenberg, R. P., Fisher, S. & Riter, J. A. (1995). Placebo washout is not a meaningful part of antidepressant drug trials. Perceptual and Motor Skills, 81, 688–690.
Hypericum Depression Trial Study Group. (2002). Effect of Hypericum perforatum (St. John’s Wort) in major depressive disorder. Journal of the American Medical Association, 287(14), 1807–1814.
khan, A., Leventhal, R. M., Khan, S. R. & Brown, W. A. (2002). Severity of depression and response to antidepressants and placebo: An analysis of the Food and Drug Administration database. Journal of Clinical Psychopharmacology, 22(1), 40–45.
Kobak, K. A., Greist, J. H., Jefferson, J. W. & Katzelnick, D. J. (2002). Fluoxetine in social phobia: A double–blind, placebo–controlled pilot study. Journal of Clinical Psychopharmacology, 22(3), 257–262.
Kramer, P. D. (1993). Listening to Prozac. New York: Viking.
Krüger, S., Goldapple, K., Kennedy, D. & Mayberg, H. S. (2002). Cerebral blood flow in bipolar disorder measured with PET: Trait effects at rest and after mood induction. European Psychiatry, 17(Suppl.1), 113.
Kupfer, D. J. & Frank, E. (2002). Placebo in clinical trials for depression: Complexity and necessity. Journal of the American Medical Association, 287(14), 1853–1854.
Lima, M. S. & Moncrieff, J. (2000). Drugs vs. placebo for dysthymia. The Cochrane Database of Systematic Reviews, 4, CD001130.
Liotti, M., Mayberg, H. S., Brannan, S. K., Mcginnis, S., Jerabek, P. & Fox, P. (2000). Differential limbic–cortical correlates of sadness and anxiety in healthy subjects: Implications for affective disorders. Biological Psychiatry, 48, 30–42.
Luborsky, L., Singer, B. & Luborsky, L. (1975). Comparative studies of psychotherapies. Archives of General Psychiatry, 32, 995–1008.
Martin, S. D., Martin, E., Rai, S. S., Richardson, M. A. & Royall, R. (2001). Brain blood flow changes in depressed patients treated with interpersonal psychotherapy or venlafaxine hydrochloride. Archives of General Psychiatry, 58, 641–648.
Mayberg, H. S., Brannan, S. K., Tekell, J. L., Silva, A., Mahurin, R. K., Mcginnis, S. & Jerabek, P. A. (2000). Regional metabolic effects of fluoxetine in major depression: Serial changes and relationship to clinical response. Biological Psychiatry, 48, 830–843.
Mayberg, H. S., Liotti, M., Brannan, S. K., Mcginnis, S., Mahurin, R. K., Jerabek, P. A., Silva, J. A., Tekell, J. L., Martin, C. C., Lancaster, J. L. & Fox, P. T. (1999). Reciprocal limbic–cortical function and negative mood: Converging PET findings in depression and normal sadness. American Journal of Psychiatry, 156(5), 675–682.
Mayberg, H. S., Silva, J. A., Brannan, S. K., Tekell, J. L., Mahurin, R. K., Mcginnis, S. & Jerabek, P. A. (2002). The functional neuroanatomy of the placebo effect. American Journal of Psychiatry, 159(5), 728–737.
Meehl, P. E. (1991). Selected philosophical and methodological papers. C.A. Anderson and K. Gunderson (Eds.). Minneapolis, MN: University of Minnesota Press.
Moncrieff, J., Wessely, S. & Hardy, R. (2004). Active placebos vs. antidepressants for depression. The Cochrane Database of Systematic Reviews, 1, CD003012.
Pardo, J. V., Pardo, P. J. & Raichle, M. E. (1993). Neural correlates of self–induced dysphoria. American Journal of Psychiatry, 150(5), 713–719.
Peet, M. & Horrobin, D. F. (2002). A dose–ranging exploratory study of the effects of ethyl–eicosapentaenoate in patients with persistent schizophrenic symptoms. Journal of Psychiatric Research, 36(1), 7–18.
Penadés, R., Boget, T., Lomeña, F., Mateos, J. J., Catalán, R., Gastó, C. & Salamero, M. (2002). Could the hypofrontality pattern in schizophrenia be modified through neuropsychological rehabilitation? Acta Psychiatrica Scandinavica, 105, 202–208.
Posternak, M. A., Zimmerman, M., Keitner, G. I. & Miller, I. W. (2002). A reevaluation of the exclusion criteria used in antidepressant efficacy trials. American Journal of Psychiatry, 159(2), 191–200.
Quitkin, F. M. (1999). Placebos, drug effects, and study design: A clinician’s guide. American Journal of Psychiatry, 156, 829–836.
Quitkin, F. M., Rabkin, J. G., Gerald, J., Davis, J. M. & Klein, D. F. (2000). Validity of clinical trials of antidepressants. American Journal of Psychiatry, 157, 327–337.
Raleigh, M. J., Mcguire, M. T., Brammer, G. L. & Yuwiler, A. (1984). Social and environmental influences on blood serotonin concentrations in monkeys. Archives of General Psychiatry, 41, 405–410.
Schwartz, J. M., Stoessel, P. W., Baxter, L. R., Martin, K. M. & Phelps, M. E. (1996). Systematic changes in cerebral glucose metabolic rate after successful behavior modification treatment of obsessive–compulsive disorder. Archives of General Psychiatry, 53, 109–113.
Taiminen, T., Syvälahti, E., Saarijärvi, S., Niemi, H., Lehto, H., Ahola, V. & Salokangas,R. K. R. (1996). Prediction of positive placebo response among chronic schizophrenic outpatients. Journal of Nervous and Mental Disease, 184(2), 109–113.
Walsh, B. T., Seidman, S. N., Sysko, R. & Gould, M. (2002). Placebo response in studies of major depression: Variable, substantial, and growing. Journal of the American Medical Association, 287(14), 1840–1847.
Zhang, X. Y., Zhou, D. F., Zhang, P. Y., Wu, G. Y., Su, J. M. & Cao, L. Y. (2001). A double–blind, placebo–controlled trial of extract of Ginkgo biloba added to haloperidol in treatment–resistant patients with schizophrenia. Journal of Clinical Psychiatry, 62(11), 878–883.
